

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技术有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

We refer to the announcement (the “**Announcement**”) of Alibaba Health Information Technology Limited (the “**Company**”) dated January 3, 2017 in relation to, among other things, the non-exempt continuing connected transactions contemplated under the services framework agreement (the “**Services Framework Agreement**”) entered into between the Company (for itself and on behalf of its subsidiaries) and Alibaba.com China Limited and Taobao China Holding Limited (for themselves and on behalf of their Subsidiaries) on December 31, 2016. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to announce that, with the approval of the Independent Board Committee, Somerley Capital Limited, a corporation licensed to carry out type 1 (dealing in securities) and type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), has been appointed as the independent financial adviser to advise the Independent Board Committee and the Independent Shareholders in connection with the entry into of the Services Framework Agreement. The letter of advice from Somerley Capital Limited in respect of the continuing connected transactions that will be entered into pursuant to the Services Framework Agreement will be included in a circular (the “**Circular**”) to be despatched by the Company. As additional time is required to prepare and finalize the Circular, including but not limited to the letter from Somerley Capital Limited, the Company expects that the Circular will be despatched on or around February 15, 2017.

For and on behalf of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
WANG Lei

Chief Executive Officer and Executive Director

Hong Kong, January 26, 2017

As at the date of this announcement, the Board comprises eight Directors, of whom (i) one is an executive Director, namely Mr. WANG Lei; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. TSAI Chung, Joseph, Ms. HUANG Aizhu and Mr. KANG Kai; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.